Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $45M | $-66M | $-84M | $-53M | 248.9% | -22.6% | 89.8% |
| 2024 | $58M | $-27M | $-44M | $-36M | 73.4% | 13.8% | 460.8% |
| 2023 | $51M | $1M | $-8M | $-7M | 7.4% | 6.1% | -85.5% |
| 2022 | $48M | $-40M | $-54M | $-12M | 45.9% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 44.54 |
| Operating Revenue | 44.54 |
| Cost Of Revenue | 18.56 |
| Gross Profit | 25.99 |
| Operating Expense | 97.04 |
| Research And Development | 17.19 |
| Selling General And Administration | 79.85 |
| Total Expenses | 115.60 |
| Operating Income | -71.05 |
| Total Operating Income As Reported | -71.05 |
| EBITDA | -66.14 |
| Normalized EBITDA | -66.14 |
| EBIT | -66.68 |
| Interest Income | 4.37 |
| Interest Expense | 17.10 |
| Net Interest Income | -12.73 |
| Other Income Expense | - |
| Interest Income Non Operating | 4.37 |
| Interest Expense Non Operating | 17.10 |
| Net Non Operating Interest Income Expense | -12.73 |
| Pretax Income | -83.78 |
| Tax Provision | 0 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -83.78 |
| Net Income From Continuing And Discontinued Operation | -83.78 |
| Net Income From Continuing Operation Net Minority Interest | -83.78 |
| Net Income | -83.78 |
| Net Income Common Stockholders | -83.78 |
| Net Income Including Noncontrolling Interests | -83.78 |
| Normalized Income | -83.78 |
| Diluted NI Availto Com Stockholders | -83.78 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.55 |
| Reconciled Cost Of Revenue | 18.56 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc.this co. | AQST | $519M | -6.20 | -15.43 | 248.9% | -6.66 |
| Strata Critical Medical, Inc. | SRTA | $542M | 13.10 | 1.94 | 14.8% | -36.28 |
| XOMA Royalty Corporation | XOMA | $532M | 16.77 | 6.34 | 37.8% | 12.14 |
| 4D Molecular Therapeutics, Inc. | FDMT | $523M | -3.73 | 1.03 | -27.7% | -3.19 |
| Pacific Biosciences of California, Inc. |
| - |
| - |
| - |
| - |
| - |
| - |
| PACB |
| $506M |
| -0.93 |
| 94.65 |
| -10214.5% |
| -7.50 |
| Arvinas, Inc. | ARVN | $499M | -6.18 | 1.15 | -18.6% | -3.23 |
| AngioDynamics, Inc. | ANGO | $497M | -14.62 | 2.72 | -18.6% | 256.27 |
| Standard BioTools Inc. | LAB | $496M | -6.62 | 1.17 | -17.7% | -4.73 |
| Evolent Health, Inc. | EVH | $493M | -0.92 | 1.19 | -128.7% | -3.68 |
| Peer Median | - | -2.33 | 1.56 | -18.6% | -3.45 | |